NYEE HomeThe New York Eye and Ear Infirmary
Patient InfoHealthcare ProfessionalsSpecialties & ServicesSupport NYEEAbout Us
  Current Research
Clinical Trials in Ophthalmology
Ophthalmology
Research

Otolaryngology
Research

Pathology
& Laboratory Medicine
Research

Plastic &
Reconstructive
Surgery
Research

Institutional
Review Board
(IRB)

 
printer-friendly version of this pagePrinter-Friendly Page large print version of this pageLarge Print Version 

A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Diabetic Macular Edema

Principal Investigator: Richard Rosen, MD  

Enrollment Status: Open  

Objective:  To evaluate the safety and efficacy of the 700 µg DEX PS DDS Applicator System (700 µg dexamethasone) and 350 µg DEX PS DDS Applicator System (350 µg dexamethasone) in patients with diabetic macular edema.

Eligibility:  Contact Principal Investigator/Coordinator. 

Contact Information:  

  • Principal Investigator: Richard Rosen, MD at (212) 979-4284
  • Study Coordinator: Julie Paa, CRC (212) 979-4024
  • Katy Tai, CR Manager (212) 979-4251

 

Home > Current Research > Clinical Trials in Ophthalmology > A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Diabetic Macular Edema